Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Phosphate | HCID 1061 | — |
| Reactant | Mannitol | HCID 6251 | — |
| Reactant | Citrate | HCID 31348 | — |
| Reactant | Vincristine Sulfate | HCID 249332 | — |
| Reactant | Sodium Acetate | HCID 517045 | — |
| Product | Vincristine | HCID 5978 | — |
Reaction Steps
Liposome-encapsulated vincristine (Vincristine Sulfate Liposome Injection) was prepared using a six vial kit. Vials 1 and 2 contained a vincristine sulfate solution (1 mg/mL Vincasar PFS® SP Pharmaceuticals LLC, Albuquerque, N. Mex.) in buffer comprising mannitol and sodium acetate, pH 4.5-4.7, vial 3 contained empty liposomes (100 mg/mL Sphingomyelin/Cholesterol liposomes, at a ratio of between about 60/40 to 50/50, or more preferably 55/45 mol %/mol %) in buffer comprising 300 mM citrate at pH 4.0, vials 4 and 5 contained an alkaline phosphate buffer (14.2 mg/mL dibasic sodium phosphate hepta hydrate), and vial 6 was an empty, sterile vial. The foregoing empty liposomes were prepared using thin film hydration and standard extrusion techniques, as described in U.S. Pat. No. 5,741,516.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US07887836B2 |
|---|
| Source dataset | uspto-grants-2011_02 |
|---|
| ORD ID | ord-eaef014de67c488a9bbda62cd6706759 |
|---|
| Source note | uspto-grants-2011_02 |
|---|